AI assistant
Sending…
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2011
Aug 18, 2011
29864_dirs_2011-08-18_8fdcf628-9165-4180-a017-09bf6e9b3c81.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2011-08-17
Reporting Person: BOGER JOSHUA S (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2011-08-17 | Common Stock | M | 4000 | $24.66 | Acquired | 731395 | Direct |
| 2011-08-17 | Common Stock | S | 4000 | $46.51 | Disposed | 727395 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2011-08-17 | Stock Option | $24.66 | M | 4000 | Disposed | 2011-12-10 | Common Stock (4000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 13286 | Indirect |
Footnotes
F1: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported at an average price of $46.51 (range $45.82 to $47.47).
F3: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Fully vested.
More from VERTEX PHARMACEUTICALS INC / MA
Major Shareholding Notification
2026
May 14
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 13